Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 9:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–39 of 39 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: metformin alone (Arm A) Clear all
Completed Phase 2 Interventional Results available

Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

NCT01476475
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine /lixisenatide Fixed Ratio Combination, Insulin glargine, Metformin (Background drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Little Rock, Arkansas • Paramount, California • Larenceville, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 7, 2026, 9:25 PM EDT
Terminated Phase 2 Interventional

Study of RO6807952 in Patients With Diabetes Mellitus Type 2

NCT01516476
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Placebo, RO6807952, liraglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 7, 2026, 9:25 PM EDT
Terminated Phase 2 Interventional Results available

DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma

NCT02815397
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Metformin
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 7, 2026, 9:25 PM EDT
Completed Phase 3 Interventional

Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone

NCT00095030
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
muraglitazar
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
108
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 105 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 7, 2026, 9:25 PM EDT
Completed Phase 2 Interventional Results available

A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263

NCT01128621
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK1292263, GSK1292263 matching placebo, Sitagliptin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 7, 2026, 9:25 PM EDT
Completed Phase 2 Interventional Results available

Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

NCT01923181
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, oral placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
632 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
40
States / cities
Tucson, Arizona • Chula Vista, California • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 7, 2026, 9:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants

NCT06679413
View directory record Official record
Conditions
Healthy Study Participants
Interventions
midazolam, metformin, bupropion, fenfluramine HCl
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 7, 2026, 9:25 PM EDT
Completed Phase 3 Interventional Results available

Comparing the Effects of Oral Contraceptive Pills Versus Metformin

NCT03229057
View directory record Official record
Conditions
PCOS
Interventions
OCP + Metformin, OCP + Placebo, Metformin + Placebo
Drug
Lead sponsor
Anuja Dokras
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 7, 2026, 9:25 PM EDT
Completed Phase 2 Interventional Results available

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin

NCT01929863
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK2330672, Placebo, Metformin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 7, 2026, 9:25 PM EDT
Recruiting Early Phase 1 Interventional

Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients

NCT05515978
View directory record Official record
Conditions
Prostate Cancer
Interventions
Metformin, Lifestyle Modification
Drug · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2036
U.S. locations
4
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 7, 2026, 9:25 PM EDT
Terminated Phase 2 Interventional

Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes

NCT00698789
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
INCB019602, Placebo, Metformin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Chula Vista, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 7, 2026, 9:25 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

RISE Adult Medication Study

NCT01779362
View directory record Official record
Conditions
Prediabetes, Type 2 Diabetes
Interventions
Metformin, Liraglutide, Glargine, Placebo
Drug
Lead sponsor
RISE Study Group
Network
Eligibility
20 Years to 65 Years
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
4
States / cities
Chicago, Illinois • Indianapolis, Indiana • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 7, 2026, 9:25 PM EDT
Not yet recruiting Phase 3 Interventional

Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis

NCT07520110
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Metformin, Matching Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
40 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
15
States / cities
Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 7, 2026, 9:25 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes

NCT00835861
View directory record Official record
Conditions
Non Insulin Dependent Diabetes, Pregnancy
Interventions
Metformin, Insulin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 7, 2026, 9:25 PM EDT
Active, not recruiting Phase 2 Interventional Results available

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

NCT02365597
View directory record Official record
Conditions
Urothelial Cancer
Interventions
Erdafitinib, Midazolam, Metformin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
25
States / cities
Sedona, Arizona • Los Angeles, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 7, 2026, 9:25 PM EDT